Pomegranate juice and its bioactive components may serve as cost-effective, next-generation non-pharmacologic anticancer therapies, particularly against colorectal and prostate cancer.
The present review was undertaken to provide current information on the impact of pomegranate juice and its bioactive elements, critically focusing on the effects on the most common six types of cancer. The inherent polyphenolic compounds of pomegranate, such as ellagitannins and punicalagin, are known to have substantial antioxidant capability which has been evaluated through in vitro and in vivo studies. These compounds' ability to avert free radicals and design metal-chelates in biological tissues have offered a useful basis to extrapolate their impact on various types of cancers.
Discussion of Results: The findings indicate that the antioxidant and anti-inflammatory properties of pomegranate possess significant antimutagenic and antiproliferative activities, which proved to be beneficial in modifying gene expression, moderating cellular mechanisms, and limiting the metastasis of cancerous cells. In addition to this, there are reports from a few clinical trials showing the potential of pomegranate ingredients to prevent and treat cancer, notably colorectal and prostate cancer. It’s been noticed that the pomegranate driven therapies may prove to be a cost-effective alternative to costly chemotherapies which often carry drug resistances and severe side effects. Such therapies could offer lesser side effects, making them potential candidates for future non-pharmacologic anticancer treatments.
